Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

829
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
829
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Translational oncology·2026
Same author

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026
Same author

Efficacy of a short multimodal workshop including stress management and communication skills training on objective structured clinical examination performance and exam-related anxiety in French medical students: a randomized controlled study.

Journal of educational evaluation for health professions·2026
Same author

PK and PK/PD Modeling of Bcl2 Inhibitor S65487 in Patients With AML and Investigation of Nonlinearity With Microdosing.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026
Same author

Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation.

Clinical pharmacokinetics·2026

Related Experiment Video

Updated: Jun 27, 2025

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

37.6K

Improving olaparib exposure to optimize adverse effects management.

Marylise Sterlé1,2,3, Alicja Puszkiel4,5,3, Chloé Burlot1,2,3

  • 1Pharmacy Department, Centre Georges-François Leclerc, Dijon, France.

Therapeutic Advances in Medical Oncology
|April 26, 2024
PubMed
Summary

This study establishes a pharmacokinetic/pharmacodynamic (PK/PD) model for olaparib, linking plasma concentrations to adverse effects like anemia. A target trough concentration of 3500-4000 ng/mL is proposed to minimize severe anemia risk in cancer patients.

Keywords:
PK/PDanaemiacreatinine increasemodellingolaparibovarian cancer

More Related Videos

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.7K
Laser Micro-Irradiation to Study DNA Recruitment During S Phase
07:11

Laser Micro-Irradiation to Study DNA Recruitment During S Phase

Published on: April 16, 2021

4.3K

Related Experiment Videos

Last Updated: Jun 27, 2025

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

37.6K
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.7K
Laser Micro-Irradiation to Study DNA Recruitment During S Phase
07:11

Laser Micro-Irradiation to Study DNA Recruitment During S Phase

Published on: April 16, 2021

4.3K

Area of Science:

  • Pharmacology
  • Oncology
  • Clinical Pharmacy

Background:

  • Olaparib is a PARP inhibitor used for breast, ovarian, prostate, and pancreatic cancers.
  • Understanding its pharmacokinetics/pharmacodynamics (PK/PD) is crucial for optimizing treatment and managing side effects.

Purpose of the Study:

  • To establish the PK/PD relationship between olaparib plasma concentrations and adverse effects (anemia, hypercreatininemia) in a real-world setting.
  • To propose a target olaparib concentration for therapeutic drug monitoring to improve patient outcomes.

Main Methods:

  • Developed two PK/PD models to describe the time-dependent changes in hemoglobin and creatinine levels in olaparib-treated patients.
  • Utilized data from 38 and 37 patients, respectively, for model development.
  • Simulated outcomes for 1000 virtual subjects to define target exposure levels.

Main Results:

  • The models accurately described the temporal changes in hemoglobin and creatinine levels.
  • Identified a target trough concentration of 3500-4000 ng/mL, above which over 20% of patients are predicted to experience grade ≥3 anemia.
  • Model parameters aligned with physiological and literature values.

Conclusions:

  • Real-world data enabled accurate modeling of hematological and renal parameters during olaparib therapy.
  • The proposed target concentration can guide therapeutic drug monitoring to mitigate olaparib-induced anemia.